0001104659-22-119575.txt : 20221116 0001104659-22-119575.hdr.sgml : 20221116 20221116170028 ACCESSION NUMBER: 0001104659-22-119575 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221110 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221116 DATE AS OF CHANGE: 20221116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 221395974 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 tm2230542d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2022

PROMIS NEUROSCIENCES INC.

(Exact name of registrant as specified in its charter)

Canada		001-41429		98-0647155
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Suite 200, 1920 Yonge Street, Toronto, Ontario				M4S 3E2
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (416) 847-6898

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, no par value per share		PMN		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Approval of the ProMIS Neurosciences Inc. Annual Incentive Plan

On November 10, 2022, the Board of Directors (“Board”) of ProMIS Neurosciences Inc. (the “Company”) approved, based on a recommendation from the Compensation Committee of the Company’s Board (the “Committee”), the ProMIS Neurosciences Inc. Annual Incentive Plan (the “Plan”).

The Plan is an annual bonus plan, to be paid solely in cash, beginning with the 2022 fiscal year. The Plan is intended to: (i) motivate behaviors that lead to a successful achievement of specific sales, financial and operational goals that support the Company’s business strategy; (ii) emphasize the link between participants’ performance and reward for meeting predetermined, specified goals; (iii) focus participants’ attention on operational effectiveness from both an earnings and an investment perspective; and (iv) promote performance orientation at the Company and communicate to employees that great responsibility carries greater reward opportunities.

The Plan authorizes an annual cash incentive to regular employees of the Company or its participating subsidiaries (each, a “Participant”). Bonus amounts will be earned by a Participant based on the achievement of various performance goals for the annual period against pre-established performance goals for the Participant’s business unit, which may include Company-wide, business unit, or other financial, operational, strategic or other goals, including individual performance goals, all as determined by the Company. Each Participant will be assigned a target award by the Company, which is the amount of bonus expressed as a percentage of base salary that they can expect to receive under the terms and conditions of the Plan if all the target goals are achieved. The maximum payout allowed under the Plan is 150% of a target award and the Company does not guarantee a minimum payment under the Plan. Bonus amounts earned will be calculated using the Participant’s annual rate of base salary as of December 1st of the applicable fiscal year.

Bonuses will be paid as soon as practicable after the end of the applicable fiscal year and are expected to be paid no later than the 15th day of the third month after the end of the applicable fiscal year (i.e., March 15, 2023 for fiscal year 2022). Notwithstanding the foregoing, all bonuses due under the Plan will be paid no later than the next December 31 following the completion of a fiscal year (i.e., by December 31, 2023 for fiscal year 2022). The Plan will be administered by the Committee, who will have all powers and discretion necessary to administer the Plan and control its operation.

The above summary of the Plan is qualified in its entirety by reference to the full text of the Plan, which is attached as Exhibit 10.53 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.53		ProMIS Neurosciences Inc. Annual Incentive Plan
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROMIS NEUROSCIENCES INC.

Date: November 16, 2022	By:	/s/Gail Farfel
		Name: Gail Farfel, Ph.D.
		Title: Chief Executive Officer

EX-10.53 2 tm2230542d1_ex10-53.htm EXHIBIT 10.53

Exhibit 10.53

ProMIS Neurosciences Inc.

Annual Incentive Plan

1.

Purpose.

The ProMIS Neurosciences Inc. Annual Incentive Plan (the “Plan”) provides the framework for establishing annual cash incentive compensation awards for each fiscal year (a “Plan Year,” currently the calendar year) of ProMIS Neurosciences Inc. (the “Company”), beginning with the 2022 Plan Year. The primary purposes of the Plan are to:

·

Motivate behaviors that lead to the successful achievement of specific sales, financial and operations goals that support the Company’s stated business strategy.

·

Emphasize the link between participants’ performance and rewards for meeting predetermined, specific goals.

·

Focus participants’ attention on operational effectiveness from both an earnings and an investment perspective.

·

Promote the performance orientation at the Company and communicate to employees that greater responsibility carries greater reward opportunities.

2.

Eligibility and Participation

Subject to the provisions set out in this Plan, only regular employees of the Company or its participating subsidiaries (“Employees”) who are hired before October 1 of a Plan Year in bonus eligible roles are eligible for a payment under this Plan for that Plan Year.

Employees hired, promoted or who transfer into a bonus-eligible position before the end of the first quarter of the Plan Year (March 31^st, or effective payroll date) are eligible for a full-year’s bonus.

Employees hired, promoted or who transfer into a bonus-eligible position between April 1 and September 30 (or effective payroll dates) will be paid a prorated bonus payment based on the number of days the Employee was in the eligible role in the Plan Year.

Employees who are absent from work for a cumulative total of ninety (90) or more days during the Plan Year will be paid a prorated bonus payment based on the number of days the Employee was not absent and in the eligible role in the Plan Year.

Employees hired, promoted, or who transfer into a bonus-eligible position October 1^st or later, are not eligible for a bonus payment under this Plan.

Employees who terminate employment prior to the bonus payment date for any reason (whether voluntary or involuntary, and with or without cause) are not eligible for, and will not earn, any payment under the Plan.

1

ProMIS Neurosciences Inc.

Annual Incentive Plan

3.

Calculation of Award

Bonus amounts will be earned based on performance against pre-established performance goals for the Employee’s business unit, which may include Company-wide, business unit, or other financial, operational, strategic or other goals, including individual performance goals, all as determined by the Company (each a “Bonus Plan”). The Company will separately communicate in writing the applicable Bonus Plan to each Employee eligible for the Plan Year.

Except as otherwise provided in Section 4 below, bonus amounts earned will be calculated using the Employee’s annual rate of base salary as of December 1^st of the Plan Year. Bonus amounts for Employees transferring between roles with distinct Bonus Plans will be calculated using the base salary rate as applicable for each role. Bonus calculations will be prorated based on changes in the Employee’s Bonus Plan, target bonus percentage, and base salary as applicable.

The Company’s human resources information system and payroll will be the data sources used for Plan eligibility and pro-rations.

4.

Target Incentive

Each Employee will be assigned by the Company a target award (the “Target Incentive”), which is the amount of bonus an Employee can expect to receive under the terms and conditions of the Plan if all the goals are achieved at target. Target is expressed as a percentage of base salary, unless otherwise stated in writing to the Employee by the Company. The Company will communicate the applicable Target Incentive to each eligible Employee in writing.

The Company may assign Target Incentives by position, by salary level, or based on other factors in its discretion. Target Incentives will be periodically reevaluated by the Company. If the job responsibilities of a position changes during the year, or base salary is increased significantly, the Company may revise the applicable Target Incentive as it deems appropriate.

A Target Incentive amount does not represent a guarantee of payment of any amount. Final awards earned will be calculated by multiplying each eligible Employee’s Target Incentive by the appropriate performance achievement percentage based on the Company’s assessment of performance against the goals set forth in the applicable Bonus Plan.

5.

Maximum

Unless otherwise stated in writing to an Employee, the maximum payout earned under this Plan is 150% of the Employee’s Target Incentive. Example: An Employee with a Target Incentive of 10% of his or her base salary has a maximum bonus opportunity equal to 15% of his or her base salary.

The Company does not guarantee a minimum payment. In general, performance below threshold levels will result in no amount earned for the Plan Year.

6.

Payment of Bonuses

Bonuses, to the extent earned, will be paid as soon as practicable after the end of the applicable Plan Year and are expected to be paid not later than the 15th day of the third month after the end of the applicable Plan Year (i.e., March 15, 2023 for the 2022 Plan Year). Notwithstanding the foregoing, all bonuses due under the terms of the Plan will be paid no later than the next December 31 following the completion of the Plan Year (i.e., by December 31, 2023 for the 2022 Plan Year).

2

ProMIS Neurosciences Inc.

Annual Incentive Plan

Notwithstanding any provision in the Plan to the contrary, compliance with all applicable laws and regulations, as well as the Company’s policies, practices and procedures, is an ongoing obligation of every Employee. Consequently, awards under Plan may be reduced or an Employee may lose eligibility for an award if the Employee has not fulfilled all performance or compliance obligations, including those of the Company’s applicable employment policies or any written agreements with the Employee.

7.

Plan Administration

The Plan will be administered by the Compensation Committee of the Board of Directors of the Company (the “Committee”). The Committee shall have all powers and discretion necessary to administer the Plan and to control its operation and may delegate responsibilities to Company officers as it deems appropriate. In this regard, the Company reserves the right to interpret this Plan document on a fully discretionary basis and to take any action, or to decline to take any action, in relation to the administration or interpretation of the Plan, including, but not limited to, determining Employee eligibility for participation in the Plan, and to determine the amount, if any, to be paid under the Plan. Nothing in this Plan is intended to create an entitlement to any Employee for any incentive payment hereunder except as Company may determine in its discretion. The Committee, has the sole authority to interpret, apply and resolve any discrepancies or disputes under the Plan. All decisions made by the Company’s Compensation Committee shall be final and binding. To the extent permitted by applicable law, the Committee may delegate all or any portion of its authority as identified herein to any individual or committee of individuals (who need not be directors), other than for awards to individuals who are executive officers of the Company.

8.

Miscellaneous

This Plan does not create or constitute a contract of employment between the Company and any of its Employees.

All awards under the Plan will be net of applicable taxes and other withholdings as determined by the human resources department.

The Company reserves the right at its sole discretion and without prior notification to amend, interpret, change, suspend, revoke, or cancel this Plan at any time including, without limitation, the right to modify performance targets previously communicated to take into consideration any changes in business circumstances. The Company also reserves the right, at its sole discretion, to reduce, modify, or terminate eligibility for bonus payments at any time based on business conditions, individual performance, Employee misconduct, Employee violation of Company policy, or other reason approved by the Committee.

Payments under the Plan are intended to be either exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), as “short-term deferrals,” or to otherwise comply with Section 409A of the Code, and the Company will construe and interpret the Plan consistent with this intent. Notwithstanding anything to the contrary, in no event will the Company or any of its subsidiaries be required to indemnify any Employee for any additional taxes imposed as a result of Section 409A of the Code.

3

ProMIS Neurosciences Inc.

Annual Incentive Plan

The Plan shall not create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and any Employee or any other person. To the extent that any person acquires a right to receive payments from the Company pursuant to the Plan, such right shall be no greater than the right of any general unsecured creditor of the Company. No Employee nor any other person may sell, assign, convey, gift, pledge, or otherwise hypothecate or alienate any bonus payment, other than by will or the laws of descent and distribution. The Plan is not intended to be subject to the requirements of the Employee Retirement Income Security Act of 1974, as amended.

4

EX-101.SCH 3 pmn-20221110.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pmn-20221110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pmn-20221110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 10, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 10, 2022
Entity File Number	001-41429
Entity Registrant Name	PROMIS NEUROSCIENCES INC.
Entity Central Index Key	0001374339
Entity Tax Identification Number	98-0647155
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	Suite 200
Entity Address, Address Line Two	1920 Yonge Street
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M4S 3E2
City Area Code	416
Local Phone Number	847-6898
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, no par value per share
Trading Symbol	PMN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 tm2230542d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001374339 2022-11-10 2022-11-10 iso4217:USD shares iso4217:USD shares 0001374339 false 8-K 2022-11-10 PROMIS NEUROSCIENCES INC. Z4 001-41429 98-0647155 Suite 200 1920 Yonge Street Toronto ON M4S 3E2 416 847-6898 false false false false Common Shares, no par value per share PMN NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://promisneurosciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2230542d1_8k.htm pmn-20221110.xsd pmn-20221110_lab.xml pmn-20221110_pre.xml tm2230542d1_ex10-53.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2230542d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2230542d1_8k.htm" ] }, "labelLink": { "local": [ "pmn-20221110_lab.xml" ] }, "presentationLink": { "local": [ "pmn-20221110_pre.xml" ] }, "schema": { "local": [ "pmn-20221110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PMN", "nsuri": "http://promisneurosciences.com/20221110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2230542d1_8k.htm", "contextRef": "From2022-11-10to2022-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://promisneurosciences.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2230542d1_8k.htm", "contextRef": "From2022-11-10to2022-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://promisneurosciences.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-119575-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-119575-xbrl.zip M4$L#!!0 ( V(<%5E[5)10P, !,, 0 <&UN+3(P,C(Q,3$P+GAS M9+5635/;,! ]MS/]#ZJOC.PX%%I" D-AH)E)@$G*YZ6CV)N@8DM&DI/07U]) MMI.0F)"$UB=Y]=[;76EW[?KA.([0$(2DG#4>JBX^ZQ\VF M@PX//GU$^JE_QAB=4HC"&CKA 6ZR/M]'YR2&&CH#!H(H+O;1-8E28^&G- *! MCGF<1*! ;V2>:FC']7=[".,5=*^!A5Q<=9H3W0>E$EGSO-%HY#(^)",N'J4; M\'@UP:XB*I43M(A(FRWJ5+\)1)15CP A^J"6$6O.-EFR^@M!2ZFT%I 0UA#B RH+K'P%:L855]WS=]%T$,3)UR$9] GZ21#N\I)1'M4P@= MI(@8@#(E*!,2P.K"14D3QKBN?-U^N<78DH3JTM:&#W53 S7!(_BITT%FH7ON M33<&YQUS/4(<1,.&DRV-H):WDB'T*:/6;]YG/L*FJU*3KEY:2MV;!\](I!+" M"W9@UXD J7DVD98VY,0<\@HI(%&01NMQIJ&44G)#<6#3(RQZJ0-]9'NP9NJC MX4AJIJ"3VQX$]!M.$C-<7-0OG9FK"Z= &.4E+6@/?OXP$<\5FR# M@%Y<=JB$9X2,=,7H5)<$]1;3OLN-2B3@*5/BV6:X8I',4HH7>QQKW\S\O\!J MEU*PL@LQOP?O*([ROXM- WF]-.I>IJF7?P%02P,$% @ #8AP5>1]4/G_ M"@ ;(< !0 !P;6XM,C R,C$Q,3!?;&%B+GAM;,V=7U/KN!G&[SO3[Z!- M;]J9$T)"NS.PA]WAY, .LRRPA'.V[4YG1[%%\.!(K.Q \NTKV99C2WIM0Z>2 MN(!@/:_\R/I%DO](_OC#=IVB%\*SA-'3T?3@<(0(C5B_05YQNY!9VD:2$HSE;/Z7 M=;Z/>?Z)XT>QDFR6G([G?:K>O1P>,KR:SP\/IY)\_7RVB1[+&XX3*XQ:1D8J2 MN=CBIL?'QY,B54D-Y7;)4[6/HXFR4^W2!0 M(?\;*]E8;AI/9^.CZ<$VBT?JX!='D+.4W)$'5!3S)-\]"Y2R1)(PJK8]QW-&QW-'T6[FCOU2;K_"2I",DE8(/L%S'K;RJH(EKL[>$ M)RP^I^]SK4=[LB^^.SS_'PK0C'=>A'N6X_1=YIN1SFU?D_<=\7V<^R,MVGGR MOB/=B/R_V,Y-RV\^O/;CFLJ-5^)3RR+9YJ(#([$R*;/H:(&+/10=0Y5WG3N+ M6OFFLC5GW"R[[!F+/#,2':S8RR0FB&4I@I;NJIJMME0]MQ*#J&B;([VF:PV2(I]5_9ED$4^>Y?"^JRPM MF?.*MY@TZK^A"0L#TQA,0T/KL9&_(ZM$=C72ACSG)7)C1Y,&Z%UW YVV]7[! M*@X"G"$.P9ZC&83J*(\LG5&ZP>D=>6:\"Z&VS#4Y-I,Z,$U-4)Q8C(%XE%I4 MBCU2\>89HELS'I!,:7. M3T, L\8IB:8+BA7 ''RJ4NO]T[)X)&DJ[QE@VM^PV,2NB8$-Z\R8RJ"H >V! MW!01J H)"YWS%SEJ%T.G@05NZ'T"9-CN8J@6!XN1[G @2448DG$>:6K&RCS#>"[5&Q5ST4IQG%[2F&Q_ M(CNP;(;.+1> S388FB@@,NS. #0J,2K42,B]P7'+DS7FNT42]70;IM M'I#1 M-A^Z*B! &L (94:+2[GOGN5>[R]C 6PR4-2/E_>0PJH=PM,C^TV-X X('RZ M'0(4B2#4CO(-TR6-&']FC<\'OV:GO@&U1ZP<:T:H5F+PL/&<-;'S R0(YO M9(AO5(K!U@V_Y>PEH1$\C(;D7J !3%O)T;3AX6,WV,=0/4A6<;Y!J@;KO5\6 M)?/3VK1-VIN:4A,>*&UCO8U,J?:-Q2W+-Q"! L#DRIQR75U=*D8^J MEJQR@H&6H9WLK*(MINIZ;J2%4\X4,%3J/5^[E"A>9O2EOI#GKZ74[=<>N$H*H8=V-T6VK M= \U^BM/@#AEA,)(Q&544PX ME(L<\9N'!VOOWR5V!4:_804(K P"E%Y[.C B8!PU(E 9@HH8_^A<9MF&\#(%&2R%ZPRT#=?"Q)M1'^YF\Z6]TF>VDX\38FS_@DP5_=. M6GH0? "F=!Z*-,0>T'3VU^7?D(KR@, UN^=8+FJ[V*V7+ 56PK*J7('085&Q M8)$$@0/L2R?BFJ%*BDJMKY6R6H8M1=+274%@M:6JOY481,7;'!F-0*N^/3;_ MY]OH41@CP&0'N\QU-V SJ7<%34T0&'08,TY6*BE26E^3'?9=V*I_4+#R-BA8 M]0P*5B$."E9#!P4KKX,"M>MRF1+11MTLTV2%@443.]6NP>BPK#-BD0:%"^P/ M;#OJ$+2/\;':9K'LFGR5 %\7'B[$!TM) 9VS]3:[;-8+;MI$07#2YIY?X@S8@::K^'IT8?!T3"3!E)E MF%ICL0[<+\/IX[)[^1#'KR1-?Z+LE2X(SA@E<7F]Q79WJ5OO]JF;'MOM!V\ M<1!(#7$(/'XC@\9/,@JIL.IJF3>:OK)T0W/,BSGLW-9" 3JW] VV]1HHH!H ML3L#**G%J%3[FQ1>KEY1#[S*=R:!A83DCJ>(=YK69HI;M0%QTVD0FC=>K3FR M'R^741ZG<^9$ONLB>2&?<8XK?V"9(;GK"9Q=IO69FS9M0!AU&@3G:M8QOJ24!(6+SU;&*#4=*ZXV'Q1JGZ:=- MEE"2P9V2IG++@]5BFX>6)" >;+X '@HI4EIO/)RO"5^)[NY'SE[SQVH-6;!\ M@-HM'YV6VYQ8I0'QTN4/X$:%H#)&+?OK#Z#M?@'T<@5(N+06J6-T0+,:-X8N M)&@@]0J2.0"O% SHU@F3?/\0HCESE9@S,I^D-< M4334O&*I3Q\$40--ZEP58>T3[R(0R4C?JRHU%^2'AWTMD>/1LL6@-EAN*(+@ M!+0%#96;[S?PMY[?9IDFT47*,'P5IJ5QO(J?:4];P&\O"(@"TQ6T;%\A1(72 M&P.?,'WBF^<\VMUR%A$BG];*ZI:K[QK=P&BWW+RI2&VB!H4&Q-I;_ (4[K- MC3P^-'HOWQ?\Y,/H;/),]JC '7S'O#')\*V) ;0;$AT1 M >$WP"9T[( ^%R3L,]V>:?Q,Z>.LX\ M!L2Z/JL;7!S])*\W, @0W^H6.@7,4#,#M)3/F559H-]D)JC(Q?:>]N:F*_%) M;%:;Q*\ESHC8\E]02P,$% @ #8AP501 '.1//0.!M-U"D_4D-/1PFB99 MH.VVEQYA"]")+#%)#O#?3[(QY8QLVAF,JWT2U):2_Z0 55Q$CU-OI">.:.R 'C5$5]F2XX-=1^ M433+I.RY7Q.B:61Y"=U;:7;1<.UNFEV>MJ2:M;LG)YWV M7Y]N1O&9II[722:.$GQ-4DM,'.HW< M7QN];:L+)5.F!?!0E%-AT7HRMB.19.R(M?\__#1,./* M;7I0)VJZ[I:EMEG[L;#<^%1ZQ66\YPAW89$'HLLNGL/7-&[-Y%,[H<:_=6+071-F*FO&<\6W@IS;6/D(;&M+CZ"XL MV\2/(WII?4B<'P-.9M5(#TR 3#L84"O58%)]3W6LV,*QJ8&[9PEDW$5E7*$- M 75Y'CW0&7,^.W?<=9FZ@^$QPE,$"/\4<]0(JD6,PJ40&>$/="%5#?Q]2R#S M5YC,J[0AHOXS(\I0Q=<0VD?&0."O,8%[%"(R'RLB-'.,(-"/K8'4WZ#>D'@T M(F(?S2GG+OC]3:L^AX CCMX9B1TE4 MZT0B<+\6AIFUFTBXS=+)]P>O^[R/K:"<49)3GR@TON63"6'<'$F(\:$EE#-* M3AH2A\:Z;S4IPH&^5RPE:CUB$%X2 S!>$OOL\]%TX M>I1\M5;F"T)_^CSTIW#T*#EKK4QL]'W[\4Z-Y=(SJ^TUAF)'R5EK)&)#SZ\^ M=^I>R2=6+,BJ(W]4 HH?,94-B\6.P>;B#^GUI264.6):6RT.F_6]U(;P?]BB M[BZSVA[*'3'!#0G%>#!9Q-\]Y/ M5SHP@3)&R6DKY6!@=9%6E/B[\;X%%"I* MHEHE!H'IC71S*',I@L]RCZV@;%$R3I\HC('8K6G6WF%@YVOP:CF48?90!@+* MKXH9ZT5?IFDF-L]U/#-L'E,H8I0T,2@/ ?=(+3'VJ=4?7<&%24 M@D8")3V$BL88E.QFX7CV?$.;*"\D9)#7VB$/C>RK$B;F/A:)U. M)/=O5:DTA%)&200#TA! [_E2C?C ! H7)0.LE(,X/EROXCD1,^I?&5%M"86, MDA&&Q*&.Q3/06#Q[YEB,DAGZ1"'R+=:GV[/K;L+9C/AWN 4+@/?]8%(/2,78 M6YAO0W+;T%6:^S*P'ZK1>TRAT'&V<(;D8>#.$F9H4K@U8(*(V*9>VSUWGDR^ MOA0T"#A[/(&BT:8(OE+./PJY%"-*M!0T*=*!T"R!MP@T$HASDC5RT<+P1?+, MDE+Y E3E.1<\IE#LB'.1'GEXZSV+1=7;ZU'Q_I$0=5\)*'S$29 T,H:,2UMI72T$!?IU3-["#W0PI P2.NJ U* MQ0O ZON^]V)O7I!^A37XC0J(Z+TB,5\9$L=NH49QA1<)41[R(7LH>]2-GWZA M"/3OS)RJW7NKW*&AS>]""RKJ2T$C@9+60D7C76]WWCX0O-SNV4&9(R:P5<+P M]G%E$\[B 9-^^9P9EC)BM5LA"0WQ%Q*/*%B9>WRL94^JF8?3VS ,D3< * MH&%!S&.?A0+OT8),4[?!2<:/H[D5KN\RD[^ZU?H8?, 0+ <-#^8F4X!PQ+LC M_7T#&DVNU@]T2I5; C&F*W-E&WL,WRP!BD-CA/IF)#"&BE"=MX]TW=@#[@6] MQ3?NEWL)K3WR'U!+ P04 " -B'!5K +4/2L6 !):P $@ '1M,C(S M,#4T,F0Q7SAK+FAT;>T]:U/;O-+?F>$_Z.1,S] YY.)<( 2:,Q "#9= $RAM MOS"*K<0&QPZR')+^^G=7LA,GL8'00-MGWN=2FEA:K?:^JY79^]^H;Y,AXY[E M.I]26B:7(LS17<-R>I]2ONBFRZG_5=?7]DP!XV"LXWU*F4(,*MGLX^-CYK&0 M<7DOJ^WL[&1'.":E!E5&L>/RN9R6_79^UM9-UJ=IR_$$=70VF61;SGTR?'PZ M&=KAMC4S%+\)%RED%T##4V,Z(3IX*ZL>S@P5L4-+:J@(AUJ>6\QKVT_AH49, M)HR2QFJ(,^R0?3MHG4V'B_CQTZ%9P:GC=5W>IP)XB)!*Z5P^G=^* $E[3)\! M!)\S/7?X+)QRNJ"%>VA& [EK)L(>"L+ M3\.!OI?N43J8#.Y2KR,'!@\DW'1.BV -3[AK,R]VCGP2,TEW?4?P<3S^P4,Y M+9S@<;&X 'P9 _ORO#D9.N!NW_(/L_*:IN524O48-> G MP7_VA"5L5MW+JI_PM,\$)0@NS1Y\:_@I57,=P1R1OAH/@!>Z^O0I)=A(9)6& M9G%>-@"[]Z]TFAQ9S#8JI,W$+FG2/JN0D3':)8U#^9?;7'[_]KK](7]XO+]_ M"3]P4R2=?NGLPO8M;/HV8;.WX6:7@%@L36:]9GKIZ):!%,).X+^Z [0#N1.#N]YECP/_BR*:]VRZU/;8$J*T#H/CA MK78;&! %$[Y:!D;^MFU2SKS;_*VTEPJ()[];!LXAXG(9P"HLH)0(O.,:8^*) ML0.;CBO$ M<1TF'UJC"LHNXZ@4\I-E&,R1*H(?86#3[P,L74G_2+30OAR!^*&LI#4MK>6$ M._U[BCBP:UB*6958:4A5I^*PEYU98C6KSLA*JBJ%)7:A[,QV<5VPCHQ+95(C MT Q7/.E? 0$BG6;%E!9VT'?2H;9D1IZ1"IX*L!2?4I[5']A,68=@I5G8:C7/ M]7FX& R3K*\$.R:6\>2.0RL63F.2V)-O)]];!C[I6HP3N1,6Z[MJC=-9QLQ/ MGBZ7C5TO6&T Y'6-12P@@.#BD I6G6XAA#1]MC -.)DP*7PRC]8, N&7 4EG MZ>P[EB(R:-T"-?N,>CYGU4 ]*S F!!8^FET"H27 5[J>N$1 !#GHU6M,;'D:S.,8!S6RZ"%SP'DYSRW[/%WFUXT#'#Z?H<(" M00,-C>BCL@ZA:=S+PGSXB?_N#4)SVJ>\9SD5 G8X5?W/O[6MW.Y>=B"'17U! MR[=9^I+VI,N*FF,U/RW<0844!N P@B\ZKA!N/_CNT3*$B<8^]R$U,[OCVC%T2/ PAJ>?:]#EZD+1G_03_I$6QQVT&?T9VD)W9PA-$ MF&Q_L*RK"CMUL7-4/2?MJ M_ZK>WLMVDO>PLB7;]=IUJW'5J+?)?O.0U+_5/N\WC^ND=G%^WFBW&Q?-)_%8 MEI:)>-Q0SX3<5+@P_S!3RY!\KE3<>8>UG^%M>54;/+IHG9,];T =:20Q -O) M%61!L,_6X>6L],Q:X=]")9^.2Z)KI>JEM.G\T') M7A8QK?Y^^J],P$#,6_7F%6G5+R]:5^\CU.'>WF.M2Y][/G4$$2Y,U#'7)UJ! MN)QHI0WCX_L@X7:),!FN[W-+6 "P/M)-ZH"QWM<%@)MP8FWEFG6K M>-JS7FT35&'H4\H:B8H!*_5AGFG0\1A09TZNF MJI>M"_#CI%F_;EVT:XUZLP:>OM&L97X?FX!V&_41!7N R*.:\ G2A'K$&S = M\SR#6$!?X:VO@0D!M>'O8<1^,7368D)G[<6A<^?M0N-5Q;Z"=FP&U+)M$!== MGB: %.+G 36,\//2B\Z01V9!@H=0AHP+2Z=VR"H@59A8[@DC'!5 *!0_O%AC MM1F-;3BZR\$^RS)Y6X!QJZF"<,TU$A1X>/EPW.\^N >>L0H#C-7\"C-ZE ^X M.PS*T;-&^ 6HIJHUZE"#/JG@PDBDH)9 P% 0GIA:R+^<^.49XA]9-@-$P8_$ M4UJ(_L'U#Z]T=ZJOS%1.U\1RDY8N:L7\0AGP#Z-:<89J5W34"*IBNI2%ITC8 MJ.>_>L;9S<'9*C*()Q%(57?*Z=Q6<5LKE9XC*/S!7Z?Q2;Y%*@0&OB[$HIS< M02CJ&9:,B/=841WZF,S?99F:A%7-[?8?U&JTWJ M_8'MCAD/,9CE'6FZF8\Q?,E*FU_]R[W)(J5BI&PR=1DW4+_:O M._;9D6/>O^&.(%;6=O(Y\MW%M+(M.&,B<6>+>5;LWFKPUPM^Y3XZ\3LK7Y_N M[]QM;=U?KL[]+"R=JEZY'("YR7R2>ONB'4DC>,$O(9 2Y<0O_@=*\]/AI9H MK22!E/&+APMC_(+[C0M>XA%,52\<02&S7-H!SZNQ"KNG1N##T_;RF>G@G']I M_J\O_VMVZ-(%AM@_K$%R%-O:/OE:[K.OQ9N=50OWS.JIZGFQ30KUIRL$+PP) M%)V6B H"C##=''"0.&M ;<)&3/>%-<0L%-P@\V(<<2S[7O[ED]XF"5F@&$&2 MO:T[_KT%V6FEXC__+N>U[5T/1MIL8+H.(XX,BS8Q2K-]# 36URAG%.31@%QX M(\D$HC'=AW')PMYXO+=S-^9UX4=A!<(>72]5+6I;":+],='%GKD@$Y>XYZ=B M][//^0?-/*="WUH!UO-KIJKEXG9ZJ[Q3_MVUNS=:Y,[W(,P=0V9L,OU>EJCI M 'P4& ),%3KNB'28[3X22]6OC\"GD7+ZE'0M&V2/6!X(HF".P8SU->$2S^K[ MMJ .O.Y93@QEN!U964750$X_4N'P Q EUQN&SKFO#ZC@/':>% M28)7>;OSRS^NAA.XLLB*Z2[M6_:X0FX '43)2RWXN_#P[(9; IB#"9;O!+F, M%Z]']^7>EW:G?-'47^_JHA7SCNO:C#JRKR>J8;$H*3Z4=Q.53/X@P5S )SJ9 M#"+G.UCG(\5\*9"DN2,7/&G9T+9)[:A%\H5DB/B]DZ'0BZ*6:N_^3#_YEN\6VV_+ MV62\7LAA )#6(Q">U5VM:*3S&YV/+^.W&OLW<;P4S_&&Y_F,/\OW\<7I8?/0 MU+ZU.^_)]P7LWHS[!98N;N@OXWXP=I[[;UB4>[.(/^*C5#3$.#-FR#-I7$"! MEV5:) [0I$+>/P;] \*DQ"QWKJ=NX> P@0-7>+L H\XZU4U2LZGGK:[R_%J< M.$5BDO:XWW'MC;@4_)TQ:@;'TI)($\T$L;PQ+?BF-9'=V(K%"TL2"<%LH"-C M+=^1S(JWD-_MH^_ZE[+0W==[QDAD,[WRTU>!W(!"OO;>P.02H'.> 9]F*<0 M"4A4HP-+0-A[3OD]5NO_@>=++SR[U%U$Q?F4RJ?BA&)2J6@X!@80C'3&1)=5 M"]CI/7DTF3S4G*LH6!X! 8+H XG1(SWN/@H3XY !5AFH1PS6M1S54:.2QUR) M+#;K37OT"F0#2;F]*Q/(<# L SP?8"L.GJ^J8";?2>=C8,4U_DV 8F SG1#4<%\I'F5L\$J2AA#T^44?+[5+4>3_)ES=V2X?5L[T2(P[%$ MH:8PB#<3Q:MN[^SQ\^=R^?7G6#&1M> ^6SP#B,4K51T]'4[_(XW#T[(0*/TN MB17-1O<)W<8*>:RAL!:JCB:8 69#@ UFP'%EN.U[3(X"7&1QD\B[PI8,P=7E M)>2V7,L>X^*/%BR-)L6!W<,3SH:6!_/ N%!'Q\(&U67?$@[&B]H&Y8:GJII& M4JQ?V* ?0P,2M1J9Y4[,8K3S5EJLF*==;J-?ON'44B>UC;QU%;B7] :V5;U;A7Q5^G=F3GP@]D!*[ M,.W!QZH'0%=DD:JZR*'$JU\SK;/Y& '8DC>YDB]XA9?A%A;FC-ZG.PQ4"K ; M2&RCBVW%]>GFEUDL*ASOU7(;]4OS?FNN'1&41[MDKH=>)KHT%VR/QBXEB-DQ0Z>+,[#B(4Y'E[A')-]SM$OX6CL M(5A?FQ^?F2T&O*UM_56 \D]@0. U(89@"">M>&)5]_%T%-+]T"U?(HB^ MXV%]K>'H&;+O.#X,A+]C+^$0QMK4 2_TCOW*D":.;D22;0-!3F?7PKPA,E\>40^9 ML4GP]2L&%J H1%RJU&RHP^4NA!/K:PAK(JWXM6PV%8*QD($!_$FGA=K,(A)J M5A2-S40!(+'\7U]# 9@'K81B"C7SUTG'E:E$.\BUJ=IVQW5\B&]MA DQ;8>! MK[$,=&_,'J^O@7W0J6<"!R$.=YQ)"(W$0U\=0W+384)HL64H/[M7H MQ*,V;CX2M#L@70.F>J'A<\^%L%-!]OR!O-(6)T0=W[,<[*G"#$.P'F0P&U:( M*NL/(.. ^$I.Q?=1 -+BD3%G?0UMMX4=6&!, VB8;\CX%^1(XL/9(XHHYA]] MQH1JCH#('++F/I8R-B/WA"2^T+-PMS"E-D7Y<@\3V*&#'*&S%.N P @(CAO5S[>L(8!$OAB'%>PF:VY')1' M*"VEDJS@2L(ZC6-$SHX8,I2ICFT6<*,'80U>(_0&+D3_'4;C1I^.@Z6Y"N#0$;&QS?OCD?L7$C&Q& MM6DS- I@;UP.NB;'2JPB77VR>C&TC&!SL]@#(X"HLG@9*CT6.2(LS:@CFBB= M0T90SP-Y@AF4") V)@A%K9"(THHL1A MM(]#@*5H2RD?*^T$"*B-#DX#BX#Z"^Z:H8!.3WIQ*\ 8I>NP>W5&',99TOIW MY<;E8(6Z$@;*)Y)C*&?1IR.K[_=!I,>N+W"6^PBX3A<+O8E6RGW -6:)@09G M&CR@BA@N: $6AWH^Q:(1!!"4 .7#5:3$SH*?UP2E 1,^@'?302VQZ(3RTTN2 M1J2(E'$>7)V.4I=* AT"+2/!F2="JD&@9(/%Q"PIZD__.I,G"B,"V0%7DQ7"U+$E<%@Q-9=L/*L,PF'OKH9L"TDHRH"]*P18=B, 1&M>D* MC(]DY3 4%DSA>Y"I]90]Z 1$,GPV+^A1NJVO+6[,P5=9S4I108LT7^(86>MD M8;I(26.B_3SN0B+0#"1'X['X?-SUC-#WR M .8CO#<.H3?:(H@.@%1C)/'DG6=(*RE7/AI9%(D(G(@_@$ 1K*TR_3.%9(F= M 7F8HF1%B2&^;S-5K8],",M$F#]F2H6P2TBN"F!K/N=H18-710 7L=M832BG M3Y5GD E >#\14 #?R2"7B&[C#1GXCRXX)1X)/(-PM%ZLD M*5SN9G*9J/Y$2 M._[?J1Y-,BQYVTD5CY"_@9C\744C=37%")*;< LK[+@=>4/%+]U2VTFZ M_;Y20APR<'S60-[CGM>W5_2U4J+>GBGZ^7PA5RKF#>V6C;1'FZ%W^M1VM*\97A5(,(ALOS,X5$ M S6%ROH1.:2"$OE:@ T,+PU#)E(0-CA 90PP"+[1&[(T]2:FCV_=,I$0B;U/ MO/>28\?\_Q\[KNK8\7?P.MH;WCAN[E]=MYYY[^5O#X)BR31WC);+Y$L8:T9? MR:>:<1Y\R$=D&#AI;G^F96XSKHW'\&TL-/E8F)))A7JQ7)#6!X4O5[X\2YX4 MV-TPR92I2C DPK?P=*IA#>ILQKODEK\(0V9\:X@VDZXTACFB=>Q+1_1+-X. MF.!=2&R#7"Y:+.56&L[B*P,KL$GH5KTX';[E0+Q%\97A;6"F^!^/*DY@\ M=\'@F;BYN+U2;+->]IA:-CFBO,OL)&EZ$3V72P>6GA!*[NKVKGZ_063[F^32 MS!QFWI$*X:9^+R'D#8X*J9D6ZX)'"=]O$;2IO'N3[0J[Y)Z( PN[Y$(FAEZ% MG%%/_ EAX?LUB&7Q]W%4Y>]^$7V[^L+?_E$^N)5]O_)M Y'?&L).1D=W1N[T M\6[_W/RQT]L>'6R=?;O@A\=?"Q?V5?WTZJ0^/,WY]_\]N[D[N_KOY8^3(35R M7[Z,]T]*AWCJ^'KFW?7'SO MW%\]:E?G8[N]W;HXU1ZN3VG]\]?+L^-!P?J:W3%YJ73_\-G6KK\8]P_E_GV] M8;3.MG<.6ORX?F84OO:RYD-#+_^L?QEOU;QV>\OX\=_O^>V;ZR^7/X]-O_OC MVS!7*-<_'['22>O+IT^*)/\'4$L#!!0 ( V(<%5B7$FCC1$ (Q: 7 M =&TR,C,P-30R9#%?97@Q,"TU,RYH=&WM7&MOW,85_;[ _H>I@ 8R0,F2 M'VEC*0+D2&D,V(Y@;5KDXRPYNSLQR:%G2,G;7]]S[\SPM2M'21O74E0$E7=) M#N_,?9F]>GTPGQS^S5Z?GQP_]G]Q]7&X?/SRQ[.? MQ>7LY]?GW^XL3%F_$(<'52UFNE!.O%77XITI9)GX+Q)QJ:Q>[.!!/'H1GRND M7>KRA3C8.?FJG+OJZ/CQQ>@6O_3E]MWG5:-U/;^ W+SC<2JK*6MF=D^.7)\<_G5Q8\^;5 M)19JK'&I5F6*95^5Z?[QXY\@*]SS!U/Q_8]O9X&6T[)L9#Z=X/6XJJ^4N,AE MV1'B;_W#V#P[??GZ7'QW_OKUQ>G9V:NW__AVYV"'/U]>G'X7/__KU=GLAV]W M#@\._KKS>RG8JTW%5+1?S$U=FX*_ T]F[^+*5\K6.I5Y9!L>),4_GIW%.ZYU M5J_PX/YS7>Z0=9V=W'CU<#]>9]$WMC).$7_#]X]G[^C_B ]W0I5_:5RM%^N= MD]D*NG*3)@NO5Z)5J^F$]$KLUGCJJSS[T)@C^N(KR_]\)"IKKG2&I^F&A96% MNC;VO5@8*Y2KY3S7;J7+I9!^W52ZE="MSJ:FJ%3I9*U-*>2UM)GSC\IT)1;: M09IBK:05NQ*>L?=^\3.^30(5(FVLQ8KYFJG 0ZK,\! ]^4B8Q2>VV]_7=R!& MENNXM43,%9A9$O77NE[QVD\.GCP)+"$*]@5QL[(:C%^+RBN)HU?2S7R;M J: M^.)SF&+?],:F.=1QLL@C<7L*YL9FRNZE)L]EY11<4OC7#D>L7S="']0V3>T) MVUKSL5V[U-.\Y_6_E"0].L<_3O84L=+Y^\6M[^@TK7:X+1$+06>@L,_51 MZU[#GS[=\5^_6\Z;#H\#Z@LRZ&T>\(V!**\J%:2]L%*FNOR/>RCOE:JG$XJ2=+04-O:!;T5T',$'KP^5:SX5G71 MJ%"JIBA0694I(+$"FITEG>6P93SH]X-^?T;]_MZDC1-;-'DZD75-\ J(BOZ+ M#AP.72T6*B7@_?\LR?#6.#X.F0. RC".HS,HFA*R(N>-T(556[62@4 L[0* M%RR\O*N ;?1(W.P6-7U+E,0@ T1VL%J-2[^WVS@OB;:3P:)]CF6C.(@ M.5Y$#T>"]N6-.YU]7S;S7^!,(S#G]-DQOG:J%J:IX7IQ13O.'A- ]!)IK57+ M)D=&VZEQ2#&CR@.EZ+H7#QBON&;N=*8EZ_1NR'+/XQ)M"G^],IREKK0EX*Y@ M9TK\F-9FKJQGRB%G"E*T>2\1.3>5*6(/T@==IOR+L)$'3FN-(4\+1 M=EOCJVR,739]5\J"K31;9GKF)21/GA\^=/%B:N/']/? MA"AH SX) 0+*10:_]@AT;(H)N6&^1Q63-I-C4O_<,N&$09Q65N?!$M@I7:JJ M5D5K'D\/Q.Z-W'8P,(U_S^EKG9%!6&-]CLP6%.QC.IE+1T26+.2RH?5)Y)E< M^^I:W)BXELY["34TO_CEO3"HZ)7DW)'W8+3:EA:E2)L"'M%7*&M3 ]V"58"P M"G%C]YN#1R3L@BR*V9R^ED8DEO]G& MAG%FX,)HK9QP6,**0*P=^:RAI$8!YBZSE5G(A0;"KS[J^V3,:@J;#![@,0;[ M)V_C&5,28I .[-V]7BG<:L65R1O 9>NA0ME^3%A/N;Y-HL-?PB"I;)QZM)7M M\0'8#E]"X@B40J\O_CELL7I,??AD"ZC^FKX+V6?\[F4N MT_?B$+0YD^L,] VVV,OIMC4(;POD>WN-NSP2LW6%I4^MG.OT2+R5A?*<>&MH M?X?]AQ['I^B*SX:P\2T\F$,)W^]Y9/,"ZD%\[9/X]182B5?]??<$MK/YLCY5 M1*V7Q9>H:P]]Y8=TEZ\^':2[W\D\91Q#I;J%.*5ZPSW(R05Y>PQ)X3E6H2!%&=KD#N MFAK.>9.UV?(>)**2\>U8U5"HG$[:%EC2+Y\FL96ET_9>3U$27D 04Y>9OM(9 M];HW*$?H!". $KLN@IBO!WG\+G>^96Q),Q]]OSFFZ[[E'.]GUCJ%O!^4Y>M! MV0LX\]KJ.@)?654Y+E 8]^)A $JU,7IEFUP,(-9=QZD?4V1JQ'&6UK5V*@XL M,#8/L=P3\PQX2N7F.@FP,FIOT-JHQ&FP6'Q%^K/BMDGG<-M&)*.5W"UR4_'9-Q28BH1;SVU M( HOA#F2-9&[$9T_&OGX!(3DA"RZL./'8J:3?E VP[+>D(%;XOR@IS6,Z&.. MMG&]#>?M:SH*[K2;9&#GE6]C]XYX&4M,">+Z.H:)',+-&>NU\<@#N85,:QJ= M G>HD8*0F5I%C^]O6;T-;J#<9.1"N$>CKF3>^& W$N6KA2_8_&+FPYZC]JT< MV17$8GCLE2RI*M_2''>BB=:4RCQX'W&!1E$D#4$F T1);++JBG1PJ#/3R8;2 M4%VY!CI5!4=3:RJKL9^[IR>GFP81G$EFE*_26D6VS(7:Z639 $ C&69#CG4L MD@MUD_G!??&]IAF*,*1Z,RB$Z(LFKW65KTE^VXVPC?%C,EE7@YPB^X>S2=WX M7M__#*K48R !*X$SBGL:K!:2KLX)4A<2E^L5NZH;\X8'I/!?((7G Z3P1G[4 M15/< X#PT_:@)X8QKQ?%X9I)PPK/ 3(\*CX'VQKWB_'W\/G!7V,,_U53VA?G M'R5NHK)FV<]Q5QST([$>DG2C(6NA/E#*AQT> M/O_$,G?/F?:#;NL^.X\)EN@RRH^5=TM(C# M<8BG^ Y^DY2E--%;!U7XG*6(^^]^OAZ>;.FB';MWY>Z!)PH[22+&QCVJ5:=D MT/E%HH*H9VB*S"$7!@P,P4XNZI!+] 8R>L&P:R3SS"1-5' ^HGCJ/O:5R5:X MB4FS+CZ@'CZGF@Q@F0FH$#X."5(!#JQ^PUMW];[:3T1O!.3P>4('5)ZV]D*G M5;HG'NV+MZ8F_P>_7&8!74XGU)Y9&GST]?/#07'YJ+GZ.Y^ <%F[%3Y5F(.->VBXD0!G@;D3,^WA!Z=@JN;@0,F ?&GA;5&) O+-8//5C=OU*'5W-C5.# MPK,?4_%K(=,<0GI&VA0X%TV^0)2A>EL^[*?A\1[K.O('O;AZ1:\=3LIV27'' MY6Z^!L$L,$^$.1I*7( =D"E;Q5FWZPZ#MAQZ0*._'XW^;8A&29].,\HHN-MZ M/X:^9R/,)&38H;+#8F$\"SV=X%-!FM?J[TO#1Q$6XDQ;Y6N5HQGPT5EF__A& MVSBLZE9D4BM)E3&R+7.MK'<37>D3$(Y.C7(3D!+WENC>Z>:2T2X[-)-SZ;1M MF?-%LOY,Y6I)A:R-TB<>;2?8%PMX*J+AAB(D@A9#94?.$+P8ECFIEF>OPCET M/E9"BVN*015VTZLC9"9M?,93AK'G=6_/E.@C6]X[_]H[##",0TG<6SN'T&NW)-P8*==)/XL9C?11'K'RTPX=8^'&'6^JS'P* ME/(I&CY=AF!?Y[YHR16@+KJT XO=CP+$^NL*UN%?K-H^?K^JW5&_6;2?3@;J MGG!(X9/0-($K&X0&2WSJZTC",6$=XBUNO/)2]P_1'LN698 0,>Y+(5[;T.%>((N/JHTH95HW420]?W$(#_BP#\ M]V$U&LH.;"E+99K[4 F:]?Q^*%T&O\3*6^*VNB&K\#$,'IPKP;V1ZSA0,SYA MZ(,6&TX[BO,%EQYNZI3E^1#1C^L[L&'?"NLU#FOY,>04WHX)$5,]UY\@WC;? M-IYER6ADC<\7WSV6S3X-.V3-.L&!IHM(-"*?M?/U?HP?RLA-VX@3)/B1)?V MY)O!B7"-J_B:55?FO>)F<$JI3]X#-K)FG:RQH3Z B.]D "%#1WR D@J386.# M_,K//E!!5%UI>(+A:&$'C.AX!YL1PD6+^M;]&:]VRC+5%L"+LF0H ,-11KG> MGG)GMO RN8&9B9_YH'0S"=0S2WI')D98:'!2P@U8Q:U32H5[I+83(\D- YU) M+[\%6;B_2>O>EV!:-]4;=\FYY;J;-(V'-!CE7K&Q>,FTH?ON&<=%9/'(FU < M[X-#&@?6?MP6X;VHP@DO%KWZT K^&7 ON&4YL$WIS'ZOR)#(9CT3EVILB&^ M98Q##K_Y^]=<)F&+4MDH-X*7SO@'WJ/5(A DLT3DDCN_$GIORIFZZU MR=6'M:\%W$@@O2J [VZAP3*Q+4P*_V*9K.-C60_( M0[;1%9A\.XWX4_L7CTX-]Z+8X+CPO)5#%F"9*DI(V!_UV4#O,O,&0PU0#@ZZ MH)_""H-2H;7W*5D2J[Y@;;]=X?[IGZMP__2AS[F%N,%>M MC^Y5,WBLU6(!NB6>NQ"+QO=JR1.^UZ4O@2.%!RC05%"*Q2"WTM4G\XG6KT;/ MS#"!?H&'!Q'[!0!""@'&^.M"INROV>%&:!<'8UODTT;9%I0TUC6R;'^1PA>( M7$/#_;Q*6Y) '(D_C-(V>?D6_^L06"O,?"#V.V3L%#K -00&8\<).R)8M]ER MRVZYPN.0B29AR)-Z)>650DA;Z@6@5I6K;*DZ,$51>3I9K2OZE 8A0N*J]$6H M]1 #)J)7@IB'H!P:RMQUH3/>RJ7Q)#>=H;!ZWH21T':(V*>40V0SG;CAKWR, M$',WY[UXD=J7TL8TY\@6#Z[ M?;#\?/'K,?V:] G_O#3]"O5_ %!+ 0(4 Q0 ( V(<%5E[5)10P, !,, M 0 " 0 !P;6XM,C R,C$Q,3 N>'-D4$L! A0#% M @ #8AP5>1]4/G_"@ ;(< !0 ( !<0, '!M;BTR,#(R M,3$Q,%]L86(N>&UL4$L! A0#% @ #8AP501 '.1&UL4$L! A0#% @ M#8AP5:P"U#TK%@ 26L !( ( !,!8 '1M,C(S,#4T,F0Q M7SAK+FAT;5!+ 0(4 Q0 ( V(<%5B7$FCC1$ (Q: 7 M " 8LL !T;3(R,S U-#)D,5]E>#$P+34S+FAT;5!+!08 !0 % $